Ipriflavone is a synthetic isoflavone designed to mimic some effects of estrogen to inhibit bone resorption and preserve bone mineral density, a key factor in maintaining mobility and preventing fractures with age. However, subsequent high-quality human trials have shown it to be no more effective than placebo and have identified significant safety concerns, leading to its decline in use.
Verdict
Outdated and ineffective for bone health with significant safety concerns.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Moderate
EVIDENCE GRADE
B
MONTHLY COST
$15 - $35
Protocol
- Historical protocols for bone density involved 200 mg taken three times daily (600 mg total).
Flags
- A major NIH-sponsored RCT found it no more effective than placebo for preventing bone loss.
- Associated with a significant risk of developing subclinical lymphocytopenia (low white blood cell count).
- Largely fallen out of favor in clinical practice for osteoporosis treatment.
- May interact with drugs metabolized by cytochrome P450 enzymes, like theophylline or caffeine.